BIOLINE RX competitors & alternatives

Similar pharmaceuticals company

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

PHOTOCURE ASA0IMT · PharmaceuticalsNorway

66% matchPublic

Similar pharmaceuticals company

Photocure ASA operates as a specialized pharmaceutical company, managing the entire lifecycle of pharmaceutical products from initial research and development through to their manufacturing, distribution, marketing, and commercialization. Its operations span a wide geographical area, encompassing the Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European nations, and the United States. Among its primary offerings is Hexvix/Cysview, a product utilized for the detection and ongoing management of bladder cancer. Furthermore, the company is advancing Cevira, an investigational treatment aimed at addressing human papilloma virus infections and precancerous lesions found on the cervix. Photocure distributes its products to pharmaceutical wholesalers, pharmacies, and hospitals, leveraging a network of license partners. Established in 1993, the company is headquartered in Oslo, Norway.

Similar pharmaceuticals company

Wize Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Hod Hasharon, Israel. The company focuses on the development and commercialization of treatments for ophthalmic and other serious medical conditions.

Similar pharmaceuticals company

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

Similar pharmaceuticals company

Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.

Verrica Pharmaceuticals Inc.VRCA · PharmaceuticalsWest Chester, United States

65% matchPublic

Similar pharmaceuticals company

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Similar pharmaceuticals company

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.

Biofrontera Inc.0DOL · PharmaceuticalsWoburn, United States

65% matchPublic

Similar pharmaceuticals company

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Similar pharmaceuticals company

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Similar pharmaceuticals company

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Similar pharmaceuticals company

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.

INVION LIMITEDIVX · Pharmaceuticals, Biotechnology & Life SciencesMelbourne, Australia

63% matchPublic

Pharmaceuticals, Biotechnology & Life Sciences

Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.